Relmada Therapeutics (RLMD) Shares Outstanding (2012 - 2026)

Relmada Therapeutics (RLMD) has 14 years of Shares Outstanding (Entity) data on file, last reported at $39.5 million in Q4 2025.

• On a quarterly basis, Shares Outstanding (Entity) rose 30.84% year-over-year to $39.5 million in Q4 2025; TTM through Dec 2025 was $39.5 million, a 30.84% increase from a year earlier, with the FY2025 full-year figure at $39.5 million, up 30.84% from the prior year.
• Shares Outstanding (Entity) for Q4 2025 stood at $39.5 million, up from $33.2 million in the prior quarter.
• Over the last five years, Shares Outstanding (Entity) for RLMD reached as high as $39.5 million in Q4 2025 and fell as low as $13.4 million in Q1 2022.
• Historically, Shares Outstanding (Entity) has averaged $27.6 million across 5 years, with a median of $30.1 million in 2022.
• Across the five-year window, Shares Outstanding (Entity) declined 19.77% in 2022 and surged 123.99% in 2023, its largest moves.
• Year by year, Shares Outstanding (Entity) stood at $17.6 million in 2021, then soared by 71.48% to $30.1 million in 2022, then changed by 0.0% to $30.1 million in 2023, then advanced by 0.25% to $30.2 million in 2024, then jumped by 30.84% to $39.5 million in 2025.
• Per Business Quant data, the three most recent Shares Outstanding (Entity) figures were $39.5 million in Q4 2025, $33.2 million in Q3 2025, and $33.2 million in Q2 2025.